GlassScriptPhysician profile
Jorge G Alamo
NPI 1063859189
$104,679.58
in general payments reported to CMS, 2019-2025
30 companies · $881 in 2025
The $881 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,733 · 2020: $47K · 2021: $48K · 2022: $613 · 2023: $726 · 2024: $451 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,057.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedplasma LLC | $101,000.00 | 2019-2021 | |
| Lilly USA, LLC | $1,027.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $639.22 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $622.75 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.68 | 2020-2022 | |
| Abbvie INC. | $124.50 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.25 | 2019-2024 | Trintellix |
| Genzyme Corporation | $110.78 | 2023-2025 | |
| Smith+Nephew, INC. | $100.03 | 2022 | |
| Shire North American Group INC | $88.96 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.44 | 2019-2023 | Xifaxan |
| Surgalign Spine Technologies, INC. | $79.81 | 2020 | |
| Acadia Pharmaceuticals INC | $77.49 | 2019 | |
| Abbott Laboratories | $64.90 | 2023 | Freestyle Libre |
| Veran Medical Technologies, INC. | $57.94 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $44.62 | 2019 | |
| Pacira Therapeutics, INC. | $39.24 | 2020 | |
| Amgen INC. | $33.79 | 2025 | Otezla, Repatha |
| Genentech USA, INC. | $32.86 | 2019 | |
| Allergan, INC. | $32.07 | 2020 | |
| Janssen Pharmaceuticals, INC | $24.37 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.29 | 2024 | Eliquis |
| Ironshore Pharmaceuticals INC. | $18.38 | 2019 | |
| Merck Sharp & Dohme LLC | $17.57 | 2022 | |
| Amarin Pharma, INC. | $17.08 | 2019 | |
| Boston Scientific Corporation | $16.57 | 2023 | Watchman Flx |
| Pfizer INC. | $16.35 | 2023 | |
| Philips North America LLC | $15.84 | 2019 | |
| Glaxosmithkline, LLC. | $15.48 | 2025 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $14.29 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Alamo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.